Loading...
Back to narrative

LFWD: Improved Capital Structure Will Support Future Cash Flow Potential

Expanding International Healthcare Access And Efficiencies Will Unlock Value

LFWD logo
LFWD
AnalystConsensusTarget
Not Invested
Published 11 May 2025

Update shared on 17 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-54.6%
7D
0.5%

Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share.

What's in the News

  • Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd. (company announcement)
  • The company reaffirmed its full year 2025 revenue guidance, targeting a range of $24 million to $26 million (company guidance)
  • Lifeward proposed amendments to its Seventh Amended and Restated Articles of Association to eliminate the par value of its ordinary shares and authorize a reverse share split at a ratio between 1 for 2 and 1 for 12, with conforming bylaw changes (company filing)
  • A special or extraordinary shareholders meeting has been scheduled for January 6, 2026, in Marlborough, Massachusetts, to vote on proposed corporate actions (meeting notice)

Valuation Changes

  • The fair value estimate remains unchanged at approximately $5.17 per share, indicating no shift in the core intrinsic value assessment.
  • The discount rate has fallen slightly from about 9.65 percent to 9.59 percent, reflecting a marginally lower perceived risk profile.
  • Revenue growth is effectively unchanged at approximately 54.6 percent, signaling stable long term top line expectations.
  • The net profit margin remains essentially flat at around 3.0 percent, indicating no material revision to long term profitability assumptions.
  • The future P/E has edged down slightly from about 52.39x to 52.32x, implying a modestly lower valuation multiple on forward earnings.

Have other thoughts on Lifeward?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.